| Literature DB >> 18431475 |
Paul Gilbert1, Daniel Ciccarone, Stuart A Gansky, David R Bangsberg, Kathleen Clanon, Stephen J McPhee, Sophia H Calderón, Alyssa Bogetz, Barbara Gerbert.
Abstract
BACKGROUND: Reducing substance use and unprotected sex by HIV-positive persons improves individual health status while decreasing the risk of HIV transmission. Despite recommendations that health care providers screen and counsel their HIV-positive patients for ongoing behavioral risks, it is unknown how to best provide "prevention with positives" in clinical settings. Positive Choice, an interactive, patient-tailored computer program, was developed in the United States to improve clinic-based assessment and counseling for risky behaviors. METHODOLOGY ANDEntities:
Mesh:
Year: 2008 PMID: 18431475 PMCID: PMC2292251 DOI: 10.1371/journal.pone.0001988
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Sample Positive Choice Educational Worksheet
Figure 2Sample Positive Choice Cueing Sheet
Figure 3Flow of Positive Choice study participants
Demographic and clinical characteristics of Positive Choice sample included in analysis
| Variable | Intervention (n = 240) | Control (n = 231) |
|
| Age, mean (SD), y | 43.9 ( 9.2 ) | 44.3 ( 9.0 ) | 0.604 |
|
| |||
| Female | 56 (23) | 45 (19) | 0.315 |
| Male | 184 (77) | 186 (81) | |
|
| |||
| Hispanic/Latino | 39 (16) | 20 (9) | 0.088 |
| Black or African-American | 118 (49) | 118 (51) | |
| White | 65 (27) | 72 (31) | |
| Other or multiple races | 18 (8) | 21 (9) | |
|
| |||
| Less than high school diploma | 47 (20) | 38 (16) | 0.470 |
| High school diploma or GED | 139 (58) | 127 (55) | |
| College degree | 34 (14) | 42 (18) | |
| Graduate or professional degree | 20 (8) | 24 (10) | |
|
| |||
| MSM or MSM/W | 122 (51) | 119 (51) | 0.588 |
| Other sexual risk | 55 (23) | 46 (20) | |
| Injecting drug use alone | 19 (8) | 25 (11) | |
| Injecting drug use & other risk(s) | 13 (5) | 19 (8) | |
| Blood transfusion or blood products | 5 (2) | 2 (1) | |
| Multiple Risks | 9 (4) | 6 (3) | |
| Don't Know or other | 17 (7) | 14 (6) | |
|
| |||
| Undetectable | 111 (46) | 102 (44) | 0.716 |
| ≤10,000 copies | 45 (19) | 55 (24) | |
| 10,001–50,000 copies | 27 (11) | 25 (11) | |
| >50,000 copies | 14 (6) | 14 (6) | |
| Don't know | 43 (18) | 35 (15) | |
|
| |||
| No | 174 (72) | 147 (64) | 0.103 |
| Yes | 46 (19) | 62 (27) | |
| Don't know | 20 (8) | 22 (9) | |
|
| |||
| Any drug use | 105 (44) | 95 (41) | 0.565 |
| Crack cocaine use | 60 (25) | 54 (23) | 0.681 |
| Methamphetamine use | 31 (13) | 41 (18) | 0.145 |
| Any risky drinking | 92 (38) | 90 (39) | 0.89 |
| Over the recommended limit | 51 (21) | 37 (16) | 0.050 |
| ≥3 binge drinking episodes | 84 (35) | 84 (36) | 0.757 |
| Any unprotected sex | 143 (60) | 141 (61) | 0.747 |
| With main partner | 99 (41) | 90 (39) | 0.612 |
| With casual partner(s) | 74 (31) | 84 (36) | 0.204 |
Men who have sex with men (MSM), or men who have sex with men and women (MSM/W)
Not mutually exclusive; participants could report multiple risky behaviors
Ongoing risky behavior at 3 and 6 months among Positive Choice participants reporting the behavior at baseline
| Worst-case sensitivity analysis (assumes ongoing risk for those lost to follow-up) | ||||
| Risky Behavior | Intervention | Control | Relative Risk |
|
| n/N (%) | n/N (%) | (95% CI) | ||
|
| ||||
| 3 months | 70/105 (67) | 78/95 (82) | 0.81 (0.689, 0.957) | 0.014 |
| 6 months | 59/105 (56) | 82/95 (86) | 0.65 (0.540, 0.785) | <0.001 |
|
| ||||
| 3 months | 48/92 (52) | 56/90 (62) | 0.84 (0.651, 1.080) | 0.172 |
| 6 months | 47/92 (51) | 53/90 (59) | 0.87 (0.666, 1.130) | 0.291 |
|
| ||||
| 3 months | 104/143 (73) | 117/141 (83) | 0.88 (0.773, 0.993) | 0.039 |
| 6 months | 88/143 (62) | 108/141 (77) | 0.80 (0.686, 0.941) | 0.007 |
Significant with Bonferroni correction (α = 0.05/3 = 0.0167)
Summary measures of change at 3 and 6 months among Positive Choice participants completing a follow-up session *
| Measure of behavior change | N | Mean (SD) | N | Mean (SD) |
|
|
| |||||
| 3 months | 82 | −4.0 (11.8) | 67 | −1.3 (21.2) | 0.346 |
| 6 months | 85 | −4.7 (11.6) | 73 | −0.7 (19.7) | 0.130 |
|
| |||||
| 3 months | 72 | −4.2 (7.0) | 66 | −2.9 (7.3) | 0.265 |
| 6 months | 71 | −3.6 (14.5) | 69 | −3.8 (11.1) | 0.899 |
|
| |||||
| 3 months | 43 | −9.7 (12.6) | 25 | −8.1 (18.7) | 0.703 |
| 6 months | 45 | −12.7 (13.6) | 31 | −13.7 (14.9) | 0.750 |
|
| |||||
| 3 months | 75 | +0.3 (0.5) | 73 | +0.2 (0.4) | 0.327 |
| 6 months | 84 | +0.4 (0.5) | 77 | +0.2 (0.5) | 0.091 |
|
| |||||
| 3 months | 53 | +0.3 (0.5) | 66 | +0.3 (0.5) | 0.707 |
| 6 months | 63 | +0.3 (0.5) | 68 | +0.3 (0.5) | 0.858 |
|
| |||||
| 3 months | 78 | −2.3 (9.2) | 88 | −1.4 (7.9) | 0.461 |
| 6 months | 89 | −2.7 (8.4) | 93 | −0.6 (5.6) | 0.042 |
Excludes participants lost to follow-up